Analysis of Inflammatory Factors Levels and Safety in the Treatment of Psoriasis with Apremilast

To analyze the levels of inflammatory factor and safety in treating psoriasis with apremilast. We selected 200 cases patients under-treated our hospital from January 2021 to 2022, divided them into control group experimental at random, 100 cases, respectively. Control received normal treatment, while treated Compare both groups on factors, skin lesions adverse drug reactions. Before had no statistical difference serum levels, but they improved after treatment. Experimental more obvious improvement treatment; it higher interleukin-10 level than group, possessed lower tumour necrosis alpha, interferon gamma, interleukin-23, interleukin-7 interleukin-6 (p<0.05). The area severity index score decreased 4 w treatment end compared before reactions rate was 7.00 % 11.00 significance (p>0.05). There a certain efficacy by apremilast, which can inhibit factors improve condition effectively. It is worth popularizing.